直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Divided Federal Circuit Panel Upholds Broadest Reasonable Interpretation Standard, Nonappealable Nature of PTAB Institution Decisions (Part I)

February 06, 2015

On February 4, 2015, a divided Federal Circuit panel in In Re Cuozzo Speed Technologies, LLC. affirmed the Board’s first final written decision in inter partes review, 2–1, holding:

  • the Federal Circuit lacks jurisdiction to review the PTO’s decision to institute IPR on direct appeal;
  • the claim construction standard in inter partes review should be the broadest reasonable interpretation standard for unexpired patents; and
  • factual claim construction Board determinations will be reviewed for substantial evidence, and legal determinations de novo, following the Supreme Court’s recent decision in Teva Pharms. USA, Inc. v. Sandoz, Inc.

In its final written decision, the Board had held three claims unpatentable as obvious under 35 U.S.C. § 103. The Board had instituted on three claims—10, 14, and 17—on grounds expressly raised only on claim 17. The Federal Circuit ultimately affirmed their holdings in full.

On whether an institution decision is directly appealable to the Federal Circuit, the majority concluded that 35 U.S.C. § 314(d) prohibits review of the institution decision even after a final decision. The majority further cited In re Hiniker Co., a 1998 opinion holding that the Federal Circuit would not set aside a flawed decision to institute reexamination—even absent a comparable “No Appeal” provision. The majority left open the possibility, however, of the institution decision being “reviewable by mandamus after the Board issues a final decision.”

Regarding the Board’s use of the BRI standard for claim construction, the majority found that “[t]here is no indication that the AIA was designed to change the claim construction standard that the PTO has applied for more than 100 years.” On the argument that IPR and PGR effectively foreclose amendment and so the standard is inappropriate, the majority found “IPR proceedings are not materially different in that respect” from other PTO proceedings and that, “[a]lthough the opportunity to amend is cabined in the IPR setting, it is thus nonetheless available.”

The majority applied the Chevron framework to consideration of the PTO’s rulemaking authority in promulgating the BRI standard, asking “if the statute is ambiguous,” then is “the agency’s interpretation [] based on a permissible construction of the statutory language”? The majority held BRI was a reasonable application of their statutory authority.

On the merits, the majority held that the Board had properly construed the claims under the BRI standard. Since there was no usage of extrinsic evidence, the majority reviewed de novo and affirmed the Board’s claim construction and obviousness determination. The majority also affirmed the denial of Cuozzo’s motion for leave to amend.

Judge Newman issued a vigorous dissent, asserting that the majority’s rulings are contrary to the legislative purpose of the AIA.

Tags

broadest reasonable interpretation (BRI), United States Court of Appeals for the Federal Circuit (CAFC), claim construction, Cuozzo Speed Technologies LLC v. Lee, Final Written Decision, Teva

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP